Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detaine… Read more
Sichuan Kelun Pharmaceutical Co Ltd (002422) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.019x
Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) has a cash flow conversion efficiency ratio of 0.019x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥537.31 Million) by net assets (CN¥28.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sichuan Kelun Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sichuan Kelun Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Howden Joinery Group Plc
PINK:HWDJF
|
0.266x |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
-0.003x |
|
Sonoco Products Company
NYSE:SON
|
0.088x |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
0.076x |
|
Macerich Company
NYSE:MAC
|
0.020x |
|
Wex Inc
NYSE:WEX
|
0.239x |
|
Lotes Co Ltd
TW:3533
|
0.037x |
|
Home BancShares Inc
NYSE:HOMB
|
0.027x |
Annual Cash Flow Conversion Efficiency for Sichuan Kelun Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual cash flow conversion efficiency of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥26.74 Billion | CN¥4.49 Billion | 0.168x | -27.54% |
| 2023-12-31 | CN¥23.02 Billion | CN¥5.34 Billion | 0.232x | +25.22% |
| 2022-12-31 | CN¥16.89 Billion | CN¥3.13 Billion | 0.185x | -8.10% |
| 2021-12-31 | CN¥14.13 Billion | CN¥2.85 Billion | 0.202x | +27.14% |
| 2020-12-31 | CN¥14.00 Billion | CN¥2.22 Billion | 0.158x | -0.58% |
| 2019-12-31 | CN¥13.91 Billion | CN¥2.22 Billion | 0.159x | -30.03% |
| 2018-12-31 | CN¥12.96 Billion | CN¥2.95 Billion | 0.228x | +147.60% |
| 2017-12-31 | CN¥11.98 Billion | CN¥1.10 Billion | 0.092x | -38.85% |
| 2016-12-31 | CN¥11.47 Billion | CN¥1.73 Billion | 0.150x | +35.54% |
| 2015-12-31 | CN¥11.16 Billion | CN¥1.24 Billion | 0.111x | -0.06% |
| 2014-12-31 | CN¥10.97 Billion | CN¥1.22 Billion | 0.111x | +6.02% |
| 2013-12-31 | CN¥10.02 Billion | CN¥1.05 Billion | 0.105x | +135.82% |
| 2012-12-31 | CN¥9.06 Billion | CN¥402.77 Million | 0.044x | +2.77% |
| 2011-12-31 | CN¥7.93 Billion | CN¥342.93 Million | 0.043x | +104.24% |
| 2010-12-31 | CN¥7.05 Billion | CN¥149.29 Million | 0.021x | -86.66% |
| 2009-12-31 | CN¥1.58 Billion | CN¥250.69 Million | 0.159x | -14.55% |
| 2008-12-31 | CN¥1.19 Billion | CN¥221.08 Million | 0.186x | -23.77% |
| 2007-12-31 | CN¥691.22 Million | CN¥168.42 Million | 0.244x | -- |